Ophthotech Corp. (OPHT)

[T695]

With about 95% institutional ownership I expect the tanking to really accelerate after the bell, with tons of funds selling and no one buying

[alchemytrader]

or $6.00

[alchemytrader]

i tried at 7.20 too...looks like really really wrong.

[T695]

On watch.... But for some reason I'm thinking we can still see a couple dollars lower

[Lone Wolf]

Very tempting. Watching...

[KOmani]

In at $7.10

About $8ish in cash and short-term equivalents.

Let's hear the conference call, where I am sure someone will ask about this.

[Trendyfoods]

Lol

[davidsson10]

Feuerstein: Sure, Fovista failed. Nothing more to say, except, $OPHT failure is good for $REGN.

[jones99]

Stifel analyst recently said $7 target of results negative. Crazy. Looks like might open $7-10 range in the am

[jboatswain]

How come P3 results differed so much from P2?

62% improvement in P2, whereas it is 2% in P3

Both randomized.

P2 24 weeks vs.P3 1 year.
449 patients vs, 1248 patients

[jimmybob]

$OPHT binary examples ->

[doingmybest]

I would not recommend judging upcoming P3 by market signals. Blinded P3 trials are kept pretty tight and you cannot read the market well nor can you trust it even if you could. I would rely on your due diligence. And, I would say the company has done a minimal number of studies to date but all of them have shown consistent impressive results. There is reason to be bullish but not because of the market movement but always be weary of binary situations. I think P3 will succeed, but that is only my opinion.

[jimmybob]

http://investorshub.advfn.com/boards/read_msg.aspx?message_id=127116486

[IPO$]

By the way, the stock is making a nice run this week. I wonder if good news is in store

[IPO$]

I wonder why the stock is up 10% today?

[jimmybob]

Binary event of the year coming ... Merry Xmas?

[IPO$]

I wonder what the market is expecting in December and January.

[doingmybest]

If both P3's are good, they could file in late Q1 and expect an approval at EOY 2017, should be best timing for approval.

[IPO$]

I wonder why the calls and puts have such very high premiums then? The premiums are typically high when FDA approval meeting is close.

[doingmybest]

I think the next meeting would be a registration filing prep meeting that would come after the P3's are published.

[IPO$]

I can not find any upcoming FDA meetings for OPHT. Any idea?

[doingmybest]

A little caution on the call but this team is very professional and very deep medically. I wonder if they will now announce both of their P3's top line data together or separately as they had stated previously.

[IPO$]

Hit $32 today.

[IPO$]

$31 looks to be the floor on this one

[IPO$]

The stock is getting ready to make a big move in my opinion

[IPO$]

Word is starting to get out about today's medical journal publication

[IPO$]

Very good news being included in the medical publication

[IPO$]

This one's on fire today

[IPO$]

Why is price down today?

[IPO$]

When is FDA approval expected?

[Raphael De La Ghetto]

1 ugly chart! no se puede!

[stocktrademan]

$OPHT recent news/filings

bullish 70.00
about to breakout

## source: finance.yahoo.com

Sat, 12 Dec 2015 12:20:00 GMT ~ 3 Small-Cap Biotech Stocks With Big News Coming in 2016


read full: http://www.fool.com/investing/general/2015/12/12/3-small-cap-biotech-stocks-with-big-news-coming-in.aspx?source=eogyholnk0000001&utm_source=yahoo&utm_medium=feed&utm_campaign=article
*********************************************************

Tue, 08 Dec 2015 18:17:19 GMT ~ OPHTHOTECH CORP. Financials


read full: http://finance.yahoo.com/q/is?s=opht
*********************************************************

Fri, 04 Dec 2015 13:00:00 GMT ~ Why Ophthotech Corporation Shares Soared Higher Last Month


read full: http://www.fool.com/investing/general/2015/12/04/why-ophthotech-corporation-shares-soared-higher-la.aspx?source=eogyholnk0000001&utm_source=yahoo&utm_medium=feed&utm_campaign=article
*********************************************************

Wed, 02 Dec 2015 12:47:14 GMT ~ Ophthotech Corporation to Present at the Oppenheimer 26th Annual Healthcare Conference

[at noodls] - December 2, 2015 - Webcast Available Through Ophthotech Website - NEW YORK--(BUSINESS WIRE)-- Ophthotech Corporation (NASDAQ: OPHT) announced today that David R. ... This is an abstract of the original ...

read full: http://www.noodls.com/view/A707B2DF58E3504CE1D10EA4A49099420A4258E3
*********************************************************

Wed, 02 Dec 2015 12:30:00 GMT ~ Ophthotech Corporation to Present at the Oppenheimer 26th Annual Healthcare Conference

[Business Wire] - Ophthotech Corporation announced today that David R. Guyer, M.D., Chief Executive Officer and Chairman of the Board, will present an overview of the Company at the Oppenheimer 26th Annual Healthcare Conference in New York City on Tuesday, December 8, 2015 at 8:35 a.m.

read full: http://finance.yahoo.com/news/ophthotech-corporation-present-oppenheimer-26th-123000502.html
*********************************************************

$OPHT charts

basic chart ## source: stockcharts.com



basic chart ## source: stockscores.com



big daily chart ## source: stockcharts.com



big weekly chart ## source: stockcharts.com



$OPHT company information

## source: otcmarkets.com

Link: http://www.otcmarkets.com/stock/OPHT/company-info
Ticker: $OPHT
OTC Market Place: Not Available
CIK code: not found
Company name: Ophthotech Corp
Incorporated In:

Business Description:

$OPHT share structure

## source: otcmarkets.com

Market Value: Not Available
Shares Outstanding: Not Available
Float: Not Available
Authorized Shares: Not Available
Par Value: Not Available

$OPHT extra dd links

Company name: Ophthotech Corp
## STOCK DETAILS ##
After Hours Quote (nasdaq.com): http://www.nasdaq.com/symbol/OPHT/after-hours
Option Chain (nasdaq.com): http://www.nasdaq.com/symbol/OPHT/option-chain
Historical Prices (yahoo.com): http://finance.yahoo.com/q/hp?s=OPHT+Historical+Prices
Company Profile (yahoo.com): http://finance.yahoo.com/q/pr?s=OPHT+Profile
Industry (yahoo.com): http://finance.yahoo.com/q/in?s=OPHT+Industry

## COMPANY NEWS ##
Market Stream (nasdaq.com): http://www.nasdaq.com/symbol/OPHT/stream
Latest news (otcmarkets.com): http://www.otcmarkets.com/stock/OPHT/news - http://finance.yahoo.com/q/h?s=OPHT+Headlines

## STOCK ANALYSIS ##
Analyst Research (nasdaq.com): http://www.nasdaq.com/symbol/OPHT/analyst-research
Guru Analysis (nasdaq.com): http://www.nasdaq.com/symbol/OPHT/guru-analysis
Stock Report (nasdaq.com): http://www.nasdaq.com/symbol/OPHT/stock-report
Competitors (nasdaq.com): http://www.nasdaq.com/symbol/OPHT/competitors
Stock Consultant (nasdaq.com): http://www.nasdaq.com/symbol/OPHT/stock-consultant
Stock Comparison (nasdaq.com): http://www.nasdaq.com/symbol/OPHT/stock-comparison
Investopedia (investopedia.com): http://www.investopedia.com/markets/stocks/OPHT/?wa=0
Research Reports (otcmarkets.com): http://www.otcmarkets.com/stock/OPHT/research
Basic Tech. Analysis (yahoo.com): http://finance.yahoo.com/q/ta?s=OPHT+Basic+Tech.+Analysis
Barchart (barchart.com): http://www.barchart.com/quotes/stocks/OPHT
DTCC (dtcc.com): http://search2.dtcc.com/?q=Ophthotech+Corp&x=10&y=8&sp_p=all&sp_f=ISO-8859-1
Spoke company information (spoke.com): http://www.spoke.com/search?utf8=%E2%9C%93&q=Ophthotech+Corp
Corporation WIKI (corporationwiki.com): http://www.corporationwiki.com/search/results?term=Ophthotech+Corp&x=0&y=0

## FUNDAMENTALS ##
Call Transcripts (nasdaq.com): http://www.nasdaq.com/symbol/OPHT/call-transcripts
Annual Report (companyspotlight.com): http://www.companyspotlight.com/library/companies/keyword/OPHT
Income Statement (nasdaq.com): http://www.nasdaq.com/symbol/OPHT/financials?query=income-statement
Revenue/EPS (nasdaq.com): http://www.nasdaq.com/symbol/OPHT/revenue-eps
SEC Filings (nasdaq.com): http://www.nasdaq.com/symbol/OPHT/sec-filings
Latest filings (otcmarkets.com): http://www.otcmarkets.com/stock/OPHT/filings
Latest financials (otcmarkets.com): http://www.otcmarkets.com/stock/OPHT/financials
Short Interest (nasdaq.com): http://www.nasdaq.com/symbol/OPHT/short-interest
Dividend History (nasdaq.com): http://www.nasdaq.com/symbol/OPHT/dividend-history
RegSho (regsho.com): http://www.regsho.com/tools/symbol_stats.php?sym=OPHT&search=search
OTC Short Report (otcshortreport.com): http://otcshortreport.com/index.php?index=OPHT
Short Sales (otcmarkets.com): http://www.otcmarkets.com/stock/OPHT/short-sales
Key Statistics (yahoo.com): http://finance.yahoo.com/q/ks?s=OPHT+Key+Statistics
Insider Roster (yahoo.com): http://finance.yahoo.com/q/ir?s=OPHT+Insider+Roster
Income Statement (yahoo.com): http://finance.yahoo.com/q/is?s=OPHT
Balance Sheet (yahoo.com): http://finance.yahoo.com/q/bs?s=OPHT
Cash Flow (yahoo.com): http://finance.yahoo.com/q/cf?s=OPHT+Cash+Flow&annual

## HOLDINGS ##
Major holdings (cnbc.com): http://data.cnbc.com/quotes/OPHT/tab/8.1
Insider transactions (yahoo.com): http://finance.yahoo.com/q/it?s=OPHT+Insider+Transactions
Insider transactions (secform4.com): http://www.secform4.com/insider-trading/OPHT.htm
Insider transactions (insidercrow.com): http://www.insidercow.com/history/company.jsp?company=OPHT
Ownership Summary (nasdaq.com): http://www.nasdaq.com/symbol/OPHT/ownership-summary
Institutional Holdings (nasdaq.com): http://www.nasdaq.com/symbol/OPHT/institutional-holdings
Insiders (SEC Form 4) (nasdaq.com): http://www.nasdaq.com/symbol/OPHT/insider-trades
Insider Disclosure (otcmarkets.com): http://www.otcmarkets.com/stock/OPHT/insider-transactions

## SOCIAL MEDIA AND OTHER VARIOUS SOURCES ##
PST (pennystocktweets.com): http://www.pennystocktweets.com/stocks/profile/OPHT
Market Watch (marketwatch.com): http://www.marketwatch.com/investing/stock/OPHT
Bloomberg (bloomberg.com): http://www.bloomberg.com/quote/OPHT:US
Morningstar (morningstar.com): http://quotes.morningstar.com/stock/s?t=OPHT
Bussinessweek (businessweek.com): http://investing.businessweek.com/research/stocks/snapshot/snapshot_article.asp?ticker=OPHT



$OPHT DD Notes ~ http://www.ddnotesmaker.com/OPHT

[akocaman]

Should we join the ride or?

[MasterofCoin15]

Get in now! the future of diabetic retinopathy is here!

[DewDiligence]

This is an oddly quiet board.

[DewDiligence]

NVS’ wet-AMD drug, RTH258 hits primary endpoint in phase-2 trial:

#msg-111253341

[Gixene]

New board.